Scientists find clues on why COVID vaccine causes chronic health problems in some
For a majority of people, the COVID vaccine doesn't cause adverse health effects — but a small percentage experience chronic symptoms that can last for months or even years.
Yale researchers recently made some discoveries about why certain people experience this condition, which they have dubbed "post-vaccination syndrome" (PVS).
In early findings, the team recognized "potential immunological patterns" that are unique to people with PVS. The hope is that this discovery will help to enable future treatments and therapies for those who are affected.
Is Mmr Vaccine Safe For Kids? Dr. Nicole Saphier Addresses Concerns As Measles Cases Rise
"This work is still in its early stages, and we need to validate these findings," said co-senior study author Akiko Iwasaki, Sterling Professor of Immunobiology at Yale School of Medicine, in a press release.
"But this is giving us some hope that there may be something that we can use for diagnosis and treatment of PVS down the road."
Read On The Fox News App
People with this condition may suffer from excessive fatigue, exercise intolerance, brain fog, insomnia and dizziness, according to the Yale researchers.
These typically develop within a day or two of vaccination and can worsen over time.
New Bat Coronavirus Discovered In China Sparks Pandemic Concerns
"It's clear that some individuals are experiencing significant challenges after vaccination. Our responsibility as scientists and clinicians is to listen to their experiences, rigorously investigate the underlying causes, and seek ways to help," said co-senior author Harlan Krumholz, professor of cardiology at YSM, in the release.
"Post-vaccination syndrome is real, and has been found [to occur] from many vaccines, including COVID," Dr. Marc Siegel, clinical professor of medicine at NYU Langone Health and Fox News senior medical analyst, told Fox News Digital.
The researchers analyzed blood samples from 42 study participants who experienced symptoms of PVS and 22 who did not.
Those with symptoms were shown to have lower levels of two types of white blood cells. People with PVS who had never had COVID also had lower levels of antibodies against the SARS-CoV-2 spike protein, likely because they tended to have fewer vaccine doses, according to the release.
"Fewer vaccine doses and no viral infection means the body's immune system has had little opportunity to develop a defense to the virus," said the researchers.
Some of the people with PVS also had higher levels of the SARS-CoV-2 spike protein, which enables the virus to penetrate and infect host cells. This has also been linked to a higher risk of developing long COVID.
"We don't know if the level of spike protein is causing the chronic symptoms, because there were other participants with PVS who didn't have any measurable spike protein — but it could be one mechanism underlying this syndrome," said Iwasaki.
In addition to the elevated spike proteins, other factors could increase the risk of post-vaccination syndrome. Those include autoimmunity, tissue damage and reactivation of Epstein-Barr virus (EBV), the researchers wrote.
"Akiko Iwasaka is a world-renowned immunologist at Yale who has studied COVID (and COVID vaccines) extensively," Siegel pointed out.
Click Here To Sign Up For Our Health Newsletter
"In this new study, she reports that in a very small percentage of those who received COVID vaccines (and experienced prolonged side effects), there may be the presence of persistent spike protein," Siegel confirmed.
"They may also experience immune disruption, which takes the form of elevations in inflammatory immune cells (CD8 and TN alpha) and a decrease in cells that help resolve inflammation and infection (CD4 helper cells)."
The researchers agreed that more studies are essential to guide diagnosis and treatment.
"We're only just starting to make headway in understanding PVS," said Krumholz. "Every medical intervention carries some risk, and it's important to acknowledge that adverse events can occur with vaccines."
For more Health articles, visit www.foxnews.com/health
"Our focus must remain on understanding what these people are experiencing through rigorous science and addressing the needs of those affected with compassion and an open mind."
Siegel agreed, adding, "This needs to be further studied in terms of understanding how common prolonged COVID vaccine side effects are and how to predict them and treat them."Original article source: Scientists find clues on why COVID vaccine causes chronic health problems in some
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
3 Healthcare Stocks Skating on Thin Ice
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six months, the industry has pulled back by 12.3%. This performance was noticeably worse than the S&P 500's 1.9% fall. Investors should tread carefully as the influx of venture capital has also ushered in a new wave of competition. Taking that into account, here are three healthcare stocks we're swiping left on. Market Cap: $48.91 billion With a history dating back to 1897 and a presence in virtually every hospital around the globe, Becton Dickinson (NYSE:BDX) develops and manufactures medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions and professionals worldwide. Why Do We Think Twice About BDX? Annual sales growth of 4.1% over the last five years lagged behind its healthcare peers as its large revenue base made it difficult to generate incremental demand 10.5 percentage point decline in its free cash flow margin over the last five years reflects the company's increased investments to defend its market position Below-average returns on capital indicate management struggled to find compelling investment opportunities BD is trading at $170.95 per share, or 11.4x forward P/E. If you're considering BDX for your portfolio, see our FREE research report to learn more. Market Cap: $8.28 billion With a unique business model combining end-of-life care and household services, Chemed (NYSE:CHE) operates two distinct businesses: VITAS, which provides hospice care for terminally ill patients, and Roto-Rooter, which offers plumbing and water restoration services. Why Does CHE Fall Short? 4.6% annual revenue growth over the last five years was slower than its healthcare peers Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 8.9 percentage points Waning returns on capital imply its previous profit engines are losing steam At $568.39 per share, Chemed trades at 22x forward P/E. Read our free research report to see why you should think twice about including CHE in your portfolio, it's free. Market Cap: $10.73 billion Formerly known as PerkinElmer until its rebranding in 2023, Revvity (NYSE:RVTY) provides health science technologies and services that support the complete workflow from discovery to development and diagnosis to cure. Why Is RVTY Risky? Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth Day-to-day expenses have swelled relative to revenue over the last five years as its adjusted operating margin fell by 8.8 percentage points Eroding returns on capital suggest its historical profit centers are aging Revvity's stock price of $91.03 implies a valuation ratio of 17.6x forward P/E. Check out our free in-depth research report to learn more about why RVTY doesn't pass our bar. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Arkansas ranks 45th for child well-being in national report, despite modest gains
LITTLE ROCK, Ark. – Arkansas ranks 45th in the nation for overall child well-being, according to the 2025 KIDS COUNT Data Book released Monday by the Annie E. Casey Foundation. The annual report evaluates how children are doing across all 50 states in four areas: economic well-being, education, health, and family and community. 6-year-old Dennis Martin still missing after disappearing in Smokies in 1969 Though Arkansas has made some gains since the COVID-19 pandemic, the state continues to fall behind on most indicators compared to national averages. One area of progress is child poverty. The number of Arkansas children living in poverty has dropped by 7,000 since 2019. Still, 21% of the state's children remain in poverty, which is higher than the national rate of 16%. 'This report shows that while there has been some improvement, too many of our children are still being left behind,' said Keesa Smith-Brantley, executive director of Arkansas Advocates for Children and Families. 'We can't be satisfied with small gains when the overall trends remain troubling.' Racial disparities remain a serious issue. Officials said Black children in Arkansas face a poverty rate of 43%. Children of two or more races have a poverty rate of 21%, while 19% of Hispanic or Latino children live in poverty. Non-Hispanic White children have the lowest poverty rate at 15%. Ohio girl with brain injury from flu complications returns home In addition to being ranked 44th for child poverty, Arkansas is in the bottom 10 states on the following indicators: Teens ages 16-19 not attending school and not working 8th graders below proficient on math level Low-birthweight babies Child and teen deaths Teens ages 10-17 who are overweight or obese Children in single-parent families Children living in high-poverty areas Teen birth rate 'If you look at the data, teens are where we're falling further behind,' Smith-Brantley said. 'We're seeing more teens out of school and unemployed, and more who are overweight or obese. These are outcomes tied directly to the decisions our leaders are or aren't making.' For more information, visit Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Epoch Times
3 hours ago
- Epoch Times
Healing Shingles Naturally: How East Meets West in Fighting Viral Pain and Brain Risk
Shingles, also known as herpes zoster, is a viral infection that causes a painful, blistering rash and often affects older adults or those with weakened immune systems. But since the COVID-19 pandemic, shingles has been appearing in unexpected age groups—raising new concerns about immunity, stress, and long-term health risks. Without timely treatment, this condition can lead to serious complications, including persistent nerve pain and even cognitive decline. In an episode of the 'Health 1+1' program, Jonathan Liu, a Canadian professor of Traditional Chinese Medicine, discussed both Western and TCM approaches to treating the infection, along with immune-boosting medicinal recipes that may help reduce the risk of shingles. The Importance of Early Treatment The primary treatment for shingles involves antiviral medications such as famciclovir or valacyclovir, which are typically taken orally. In more severe cases, intravenous acyclovir may be used, particularly in hospitalized or immunocompromised patients. Liu emphasized that early intervention is crucial. Ideally, antiviral therapy should begin before blisters appear. The medication works by suppressing viral replication rather than repairing tissue damage; therefore, starting treatment more than three days after the onset of blisters may significantly reduce their effectiveness.